Investigation of the Effects of Angling as Supportive Therapy in Schizophrenia Treatment on Serum Parameters, Anxiety, Depression, and Quality of Life
Angling as a Supportive Therapy in the Treatment of Schizophrenia
This study aims to evaluate the effects of recreational fishing (angling) as a supportive therapeutic intervention in individuals diagnosed with schizophrenia. Schizophrenia is a chronic psychiatric disorder characterized by disturbances in thinking, perception, emotion, and behavior, often accompanied by negative symptoms such as social withdrawal, anhedonia, and cognitive impairment, which significantly reduce quality of life.
Recreational activities, particularly those involving nature-based engagement, have been shown to support psychological well-being through stress reduction, improved attention, and enhanced mood regulation. Angling is considered a mindfulness-like recreational activity that promotes relaxation, concentration, and emotional regulation, potentially offering benefits for individuals with psychiatric conditions.
In this randomized controlled study, participants with schizophrenia will engage in a structured recreational fishing program in addition to standard care. The effects of the intervention will be evaluated on biochemical serum parameters, anxiety and depression levels, and quality of life outcomes. The study also aims to assess the psychosocial well-being of participants and determine the feasibility of integrating angling as an adjunctive non-pharmacological intervention in schizophrenia care.
The findings are expected to contribute to evidence-based complementary treatment approaches in psychiatric rehabilitation.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
Center
-
Elâzığ, Center, Türkei (türkiye), 25240
- Rekrutierung
- Fırat University
-
Kontakt:
- Gülcan B Bahçecioğlu Turan
- Telefonnummer: 506 557 60 86
- E-Mail: gulcanbahcecioglu@firat.edu.tr
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
Akzeptiert gesunde Freiwillige
Beschreibung
Inclusion Criteria:
- Adults aged 18 years and older
- Able to communicate verbally
- Diagnosed with schizophrenia
- Able to provide written informed consent
Exclusion Criteria:
- Presence of comorbid psychiatric disorders other than schizophrenia
- Patients in the acute psychotic (attack) phase
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Unterstützende Pflege
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Single
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Kein Eingriff: Kontrolle
|
|
|
Experimental: recreational fishing (angling)
|
Fishing will be done.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Quality of Life Scale for Schizophrenia Patients
Zeitfenster: Baseline and immediately after the 8-week intervention.
|
Developed by Heinrich et al. to assess the quality of life of schizophrenia patients, the Turkish validity and reliability study was conducted by Soygür et al.
Administered in a semi-structured interview format, the scale evaluates the individual's symptoms and level of functioning over the past four weeks.
It consists of 21 items and four sub-dimensions: interpersonal relationships, occupational role, mental symptoms, and daily activities.
Scores on the scale range from 0 to 126, with higher scores indicating better quality of life.
|
Baseline and immediately after the 8-week intervention.
|
|
UCLA Loneliness Scale
Zeitfenster: Baseline and immediately after the 8-week intervention.
|
The UCLA Loneliness Scale-Short Form (ULS-8) is an 8-item self-report instrument used to assess perceived loneliness.
Each item is rated on a 4-point Likert scale ranging from 1 ("Never") to 4 ("Always").
Two items are reverse scored.
Total scores range from 8 to 32, with higher scores indicating greater perceived loneliness.
|
Baseline and immediately after the 8-week intervention.
|
|
The Positive and Negative Syndrome Scale
Zeitfenster: Baseline and immediately after the 8-week intervention.
|
The Positive and Negative Syndrome Scale : he Positive and Negative Syndrome Scale (PANSS), developed by Kay et al., is a semi-structured clinician-rated instrument consisting of 30 items scored on a 7-point scale (1 = absent to 7 = extreme).
The scale comprises three subscales: positive symptoms (7 items; score range: 7-49), negative symptoms (7 items; score range: 7-49), and general psychopathology (16 items; score range: 16-112).
Total PANSS scores range from 30 to 210, with higher scores indicating more severe psychopathology and poorer clinical status.
|
Baseline and immediately after the 8-week intervention.
|
|
Serum Beta-Endorphin Concentration
Zeitfenster: Baseline and immediately after the 8-week intervention.
|
Venous blood samples will be collected to measure serum beta-endorphin concentration.
Changes in serum beta-endorphin levels will be evaluated to assess the biological effects of the intervention.
|
Baseline and immediately after the 8-week intervention.
|
|
Serum Serotonin Concentration
Zeitfenster: Baseline and immediately after the 8-week intervention.
|
Venous blood samples will be collected to measure serum serotonin concentration.
Changes in serum serotonin levels will be evaluated to assess the biological effects of the intervention.
|
Baseline and immediately after the 8-week intervention.
|
|
Serum Cortisol Concentration
Zeitfenster: Baseline and immediately after the 8-week intervention.
|
Venous blood samples will be collected to measure serum cortisol concentration.
Changes in serum cortisol levels will be evaluated to assess the biological effects of the intervention.
|
Baseline and immediately after the 8-week intervention.
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 2026/09-43
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .